Telo Genomics Receives Approval from the Intellectual Property Ontario Program (IPON)
Telo Genomics (TSXV: TELO, OTCQB: TDSGF) has received approval for the IPON program, which provides up to CAD 80,000 in IP cost reimbursement plus strategic guidance. The company holds 23 patents (20 granted) covering its TeloView technology across Canada, US, and Europe. Recent patent applications for TeloViewSMM, their flagship product for smoldering multiple myeloma (SMM), would extend protection until 2043. The TeloViewSMM test, clinically validated with Mayo Clinic and Dana Farber Institute, is available as a CLIA laboratory developed test, offering non-invasive risk assessment for SMM patients with an estimated market of over 500,000 tests annually.
Telo Genomics (TSXV: TELO, OTCQB: TDSGF) ha ricevuto l'approvazione per il programma IPON, che fornisce fino a CAD 80.000 come rimborso per i costi di proprietà intellettuale, oltre a guida strategica. L'azienda detiene 23 brevetti (di cui 20 concessi) riguardanti la sua TeloView technology in Canada, Stati Uniti ed Europa. Le recenti domande di brevetto per TeloViewSMM, il loro prodotto di punta per il mieloma multiplo smoldering (SMM), estenderebbero la protezione fino al 2043. Il TeloViewSMM test, convalidato clinicamente presso la Mayo Clinic e il Dana Farber Institute, è disponibile come test sviluppato da laboratorio CLIA, offrendo una valutazione del rischio non invasiva per i pazienti SMM con un mercato stimato di oltre 500.000 test all'anno.
Telo Genomics (TSXV: TELO, OTCQB: TDSGF) ha recibido la aprobación para el programa IPON, que proporciona hasta CAD 80,000 en reembolso de costos de propiedad intelectual, además de orientación estratégica. La empresa posee 23 patentes (20 otorgadas) que cubren su TeloView technology en Canadá, EE. UU. y Europa. Las solicitudes de patente recientes para TeloViewSMM, su producto insignia para el mieloma múltiple en etapa smoldering (SMM), extenderían la protección hasta 2043. La TeloViewSMM test, validada clínicamente con la Clínica Mayo y el Instituto Dana Farber, está disponible como una prueba desarrollada por laboratorio CLIA, ofreciendo una evaluación de riesgo no invasiva para pacientes SMM con un mercado estimado de más de 500,000 pruebas anuales.
Telo Genomics (TSXV: TELO, OTCQB: TDSGF)은 지식 재산 비용 환급을 위한 IPON 프로그램 승인을 받아 최대 CAD 80000을 제공받으며, 전략적 지침도 함께 받을 수 있습니다. 이 회사는 캐나다, 미국 및 유럽 전역에서 자신의 TeloView technology에 대한 23개의 특허(20개 승인됨)를 보유하고 있습니다. 최근 smoldering 다발성 골수종(SMM)을 위한 주력 제품 TeloViewSMM에 대한 특허 출원이 2043년까지 보호를 연장할 것입니다. TeloViewSMM test는 메이요 클리닉 및 다나 파버 연구소와 임상적으로 검증되었으며, CLIA 실험실에서 개발된 테스트로 제공되며, SMM 환자를 위한 비침습적인 위험 평가를 제공하며, 연간 500,000회 이상의 테스트 시장이 예상됩니다.
Telo Genomics (TSXV: TELO, OTCQB: TDSGF) a reçu l'approbation du programme IPON, qui offre jusqu'à 80 000 CAD de remboursement des coûts de propriété intellectuelle, ainsi qu'une orientation stratégique. La société détient 23 brevets (20 accordés) couvrant sa TeloView technology au Canada, aux États-Unis et en Europe. Des demandes de brevet récentes pour TeloViewSMM, leur produit phare pour le myélome multiple smoldering (SMM), pourraient prolonger la protection jusqu'en 2043. Le TeloViewSMM test, validé cliniquement avec la Mayo Clinic et l'Institut Dana Farber, est disponible en tant que test développé par un laboratoire CLIA, offrant une évaluation des risques non invasive pour les patients SMM avec un marché estimé de plus de 500 000 tests par an.
Telo Genomics (TSXV: TELO, OTCQB: TDSGF) hat die Genehmigung für das IPON-Programm erhalten, das bis zu 80.000 CAD an Erstattungen für IP-Kosten sowie strategische Beratung bietet. Das Unternehmen hält 23 Patente (20 erteilt), die seine TeloView technology in Kanada, den USA und Europa abdecken. Jüngste Patentanmeldungen für TeloViewSMM, ihr Hauptprodukt für das smoldering multiple Myelom (SMM), würden den Schutz bis 2043 verlängern. Der TeloViewSMM test, klinisch validiert mit der Mayo Clinic und dem Dana Farber Institute, ist als von CLIA entwickelter Test verfügbar und bietet eine nicht-invasive Risikobewertung für SMM-Patienten mit einem geschätzten Markt von über 500.000 Tests jährlich.
- Secured up to CAD 80,000 in IP cost reimbursement through IPON program
- Strong IP portfolio with 20 out of 23 patents already granted
- Recent patent applications would extend protection until 2043
- TeloViewSMM test commercially available as CLIA laboratory developed test
- Large market potential with estimated 500,000 tests per year
- None.
Toronto, Ontario--(Newsfile Corp. - November 19, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, is pleased to announce that its application to the IPON program (Intellectual Property Ontario) was approved. The IPON program leverages the innovation of Ontario enterprises in securing and expanding their intellectual property (IP) portfolio. The program provides training, advisory services and financial support. Within the program Telo may receive up to CAD 80,000 of reimbursement for its prospective IP costs in addition to strategic input and guidance.
Telo Genomics holds an IP patent portfolio of 23 patents and pending patent applications in Canada, US and Europe. The portfolio includes patents that govern its core 3D telomere technology TeloView, and disease/ application specific patents including hematological disorders, prostate cancer, Alzheimer's disease and circulating tumor cells (liquid biopsy) technology. Twenty out of the twenty-three patents are fully granted.
The most recent patent applications filed by Telo support intellectual property protection of its flagship product for smoldering multiple myeloma TeloViewSMM. The Company filed two patent applications in 2022 and 2023. These patents are now in the international phase (PCT) having been filed in Canada, the US and Europe. These 2 inventions provide protection for Telo's methods to stratify smoldering myeloma patients into their respective risk group, a major unmet clinical need. When granted these patents would protect Telo's technology into 2043.
Telo's flagship prognostic test TeloViewSMM for smoldering multiple myeloma (SMM) patients was clinically validated in collaboration with the Mayo Clinic and Dana Farber Institute of Cancer. The test is now available as a CLIA laboratory developed test (LDT). SMM patients are commonly not treated until they progress to full stage multiple myeloma (MM), a deadly incurable blood cancer. TeloViewSMM with the best reported sensitivity for the assessment of this disease, stratifies SMM into a high-risk group that can benefit from immediate treatment intervention to delay and potentially avoid progression to full stage MM. Further, the test also confirms the stability of the SMM disease in low-risk patients. These patients can be monitored over time using the TeloViewSMM test without exposing these patients to unnecessary invasive sample collections and debilitating chemotherapy treatments. Critically, TeloViewSMM can be used periodically as a non-invasive liquid biopsy test that can be performed using a simple blood draw. Recent demographic studies have shown that SMM prevalence provides a significant market opportunity with an estimated
"We are thrilled to join the IPON program. The program is highly competitive and only select technology developers with a strong and meaningful innovation footprint are considered," said Sherif Louis, Telo's President and CTO. "Telo holds a robust patent portfolio that protects all the IP aspects of our business. We are continuously reviewing our IP strategy and technology development to expand this portfolio. We were indeed forward thinking with our recent smoldering myeloma filings that provide protection for our TeloViewSMM test until 2043."
About TELO
Telo Genomics Corp. is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining our team's considerable expertise in quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to recognize disease associated genetic instability, Telo is developing simple and accurate products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of our proprietary technology have been substantiated in 160+ peer reviewed publications and in 30+ clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer's disease. Our lead application, TELO-MM is being developed to provide important, actionable information to medical professionals in the treatment of multiple myeloma, a deadly form of blood cancer. For more information, please visit www.telodx.com.
For further information, please contact:
Sherif Louis,
President & CTO
Telo Genomics
416-673-8487
www.telodx.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as such term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
Certain information contained herein may constitute "forward-looking information" under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "intends", "will", or variations of such words and phrases or statements that certain actions, events or results "will" occur. Forward-looking statements regarding the clinical efficacy of products, commercial viability of products, use of proceeds, and the ability of the TeloView® platform to deliver personalized medicine resulting in better treatments and outcomes are based on the Company's estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/230533
FAQ
What is the market size for Telo Genomics' (TDSGF) TeloViewSMM test?
How many patents does Telo Genomics (TDSGF) currently hold?
What is the IPON program approval worth to Telo Genomics (TDSGF)?
How long will Telo Genomics' (TDSGF) TeloViewSMM patent protection last?
